Review Article
Caring for Patients with CRF: Rewards and Benefits
| (a) HD treatment goals or HD clinical performance measures |
| | (1) | Prevalance of AV Fistula | | (2) | Dialysis ≥3 times/week | | (3) | Dialysis duration ≥4 hr | | (4) | Arterial blood flow rate (QB) ≥ 300 mL/min | | (5) | Kt/V ≥ 1.4 | | (6) | Intradialytic body weight gain <4% | | (7) | Mean arterial BP ≤ 105 mmHg | | (8) | Transferrin Saturation = 30–50% | | (9) | Serum Ferritin = 200–500 ng/mL | | (10) | Hemoglobin = 10–12 gm/dL | | (11) | Phosphorus = 3.5–5.5 mg/dL | | (12) | Calcium = 8.8–10 mg/dL | | (13) | Calcium X Phosphorus < 55 mg2/dL2 | | (14) | PTH = 150–600 pg/mL | | (15) | Serum albumin > 3.5 gm/dL | | (16) | Bicarbonate > 20 mEq/L | | (17) | Hepatitis B & C seroconversion = 0% |
|
|
HD: hemodialysis; AV Fistula: arteriovenous fistula; Kt/v: hemodialysis adequacy; BP: blood pressure; PTH: parathyroid hormone.
|
| (b) PD treatment goals or PD clinical performance measures |
| | (1) | Total (residual kidney + peritoneal) Kt/Vurea ≥ 1.7 per week or total creatinine clearance ≥ 50 L/week/1.73 m2 | | (2) | Peritoneal net ultrafiltration in anuric patients ≥ 1.0 L/day | | (3) | Albumin ≥ 3.5 g/dL | | (4) | Hemoglobin ≥ 10.0 and ≤ 12.0 g/dL | | (5) | Transferrin saturation = 30–50% | | (6) | Serum ferritin ≥ 200 and ≤500 μg/L | | (7) | Phosphorus ≥ 3.5 and ≤ 5.5 mg/dL | | (8) | Calcium × Phosphorus < 55 mg2/dL2 | | (9) | Intact PTH ≥150 and ≤600 pg/mL | | (10) | Predialysis mean arterial blood pressure < 105 mmHg | | (11) | Clinic peritonitis rate <1 episode/24 patient-months | | (12) | Hepatitis B & C seroconversion = 0% |
|
|
PD: peritoneal dialysis; Kt/v: hemodialysis adequacy; PTH: parathyroid hormone.
|
